Aignostics Announces New State-of-the-Art Pathology Foundation Model
Atlas 2 sets new industry standard and achieves best-in-class performance and computational efficiency
BERLIN and NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Today, Aignostics announced research results for Atlas 2, an updated version of its pathology foundation model. Built in collaboration with Mayo Clinic, LMU Munich and Charité – Universitätsmedizin Berlin, Atlas 2 represents a new state-of-the-art for pathology foundation models across three key dimensions: the highest average performance across 80 public benchmarks, the most extensive training dataset with over 5 million slide images, and the largest model architecture at approximately 2 billion parameters.
Beyond its scale, the model also demonstrates best-in-class robustness, a critical requirement for clinical deployment, and includes clinical-grade regulatory documentation to support integration into medical devices. Alongside the full model, the team have developed distilled versions that also achieve best-in-class performance among compute-efficient model sizes, enabling broad adoption across diverse healthcare settings.
"Atlas 2 embodies our commitment to delivering not just the most advanced AI technology, but the most clinically viable and deployable solutions," said Maximilian Alber, Co-Founder and CTO of Aignostics. "By rigorously evaluating our models across public benchmarks while maintaining clinical-grade regulatory documentation, we're ensuring these advances can be easily integrated into clinical workflows."
Aignostics will deploy Atlas 2 across its product portfolio, including Atlas H&E-TME, its application for tumor microenvironment profiling in H&E slides. Atlas 2 will also be available for licensing.
"Atlas 2 demonstrates the continued strength of our collaboration with Aignostics," said Jim Rogers, CEO, Mayo Clinic Digital Pathology. "These results show real progress in developing AI tools that can transform pathology for the benefit of patients."
About Aignostics
Aignostics is an artificial intelligence company that turns complex pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Aignostics' latest product, Atlas H&E-TME, is a self-service application for comprehensive tumor microenvironment profiling in H&E images at single-cell resolution, empowering researchers with unprecedented precision and scalability. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world's largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York.
More information at: www.aignostics.com
Follow us on LinkedIn: www.linkedin.com/company/aignostics
Media Contact: Lisa Zheng, [email protected]
Logo - https://mma.prnewswire.com/media/2540827/Aignostics_updated_Logo.jpg
Share this article